453 related articles for article (PubMed ID: 27121148)
21. Biological correlates of elevated soluble TREM2 in cerebrospinal fluid.
Winfree RL; Dumitrescu L; Blennow K; Zetterberg H; Gifford KA; Pechman KR; Jefferson AL; Hohman TJ;
Neurobiol Aging; 2022 Oct; 118():88-98. PubMed ID: 35908327
[TBL] [Abstract][Full Text] [Related]
22. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
23. Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer's disease.
Zhao A; Jiao Y; Ye G; Kang W; Tan L; Li Y; Deng Y; Liu J;
J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36519540
[TBL] [Abstract][Full Text] [Related]
24. Clinical Utility of Cerebrospinal Fluid Aβ42 and Tau Measures in Diagnosing Mild Cognitive Impairment in Early Onset Dementia.
Hosseini AA; Brown T; Mannino L; Gran B; Junaid K; Mukaetova-Ladinska EB
J Alzheimers Dis; 2022; 87(2):771-780. PubMed ID: 35404281
[TBL] [Abstract][Full Text] [Related]
25. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
[TBL] [Abstract][Full Text] [Related]
26. Microglial Reactivity Correlates with Presynaptic Loss Independent of β-Amyloid and Tau.
Lan G; Chen X; Yang J; Sun P; Cai Y; Li A; Zhu Y; Liu Z; Ma S; Guo T;
Ann Neurol; 2024 May; 95(5):917-928. PubMed ID: 38356322
[TBL] [Abstract][Full Text] [Related]
27. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
[TBL] [Abstract][Full Text] [Related]
28. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
29. TREM2 ectodomain and its soluble form in Alzheimer's disease.
Yang J; Fu Z; Zhang X; Xiong M; Meng L; Zhang Z
J Neuroinflammation; 2020 Jul; 17(1):204. PubMed ID: 32635934
[TBL] [Abstract][Full Text] [Related]
30. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers.
Suárez-Calvet M; Kleinberger G; Araque Caballero MÁ; Brendel M; Rominger A; Alcolea D; Fortea J; Lleó A; Blesa R; Gispert JD; Sánchez-Valle R; Antonell A; Rami L; Molinuevo JL; Brosseron F; Traschütz A; Heneka MT; Struyfs H; Engelborghs S; Sleegers K; Van Broeckhoven C; Zetterberg H; Nellgård B; Blennow K; Crispin A; Ewers M; Haass C
EMBO Mol Med; 2016 May; 8(5):466-76. PubMed ID: 26941262
[TBL] [Abstract][Full Text] [Related]
31. Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer's disease.
Lim B; Fowler C; Li QX; Rowe C; Dhiman K; Gupta VB; Masters CL; Doecke JD; Martins RN; Collins S; Diamandis EP
Neurosci Lett; 2020 Jul; 731():135078. PubMed ID: 32450185
[TBL] [Abstract][Full Text] [Related]
32. Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting.
Malnar M; Kosicek M; Bene R; Tarnik IP; Pavelin S; Babic I; Brajenovic-Milic B; Hecimovic H; Titlic M; Trkanjec Z; Demarin I; Hecimovic S
Acta Neurobiol Exp (Wars); 2012; 72(3):264-71. PubMed ID: 23093013
[TBL] [Abstract][Full Text] [Related]
33. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status.
Piccio L; Deming Y; Del-Águila JL; Ghezzi L; Holtzman DM; Fagan AM; Fenoglio C; Galimberti D; Borroni B; Cruchaga C
Acta Neuropathol; 2016 Jun; 131(6):925-33. PubMed ID: 26754641
[TBL] [Abstract][Full Text] [Related]
34. Association between CSF Aβ42 and amyloid negativity in patients with different stage mild cognitive impairment.
He B; Wang L; Xu B; Zhang Y;
Neurosci Lett; 2021 May; 754():135765. PubMed ID: 33667602
[TBL] [Abstract][Full Text] [Related]
35. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
[TBL] [Abstract][Full Text] [Related]
36. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
[TBL] [Abstract][Full Text] [Related]
37. Heterogeneity of Cerebrospinal Fluid Biomarkers Profiles in Individuals with Distinct Levels of Cognitive Decline: A Cross-Sectional Study.
Pais M; Loureiro J; do Vale V; Radanovic M; Talib L; Stella F; Forlenza O
J Alzheimers Dis; 2021; 81(3):949-962. PubMed ID: 33843685
[TBL] [Abstract][Full Text] [Related]
38. White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
van Waalwijk van Doorn LJC; Ghafoorian M; van Leijsen EMC; Claassen JAHR; Arighi A; Bozzali M; Cannas J; Cavedo E; Eusebi P; Farotti L; Fenoglio C; Fortea J; Frisoni GB; Galimberti D; Greco V; Herukka SK; Liu Y; Lleó A; de Mendonça A; Nobili FM; Parnetti L; Picco A; Pikkarainen M; Salvadori N; Scarpini E; Soininen H; Tarducci R; Urbani A; Vilaplana E; Meulenbroek O; Platel B; Verbeek MM; Kuiperij HB
J Alzheimers Dis; 2021; 79(1):163-175. PubMed ID: 33252070
[TBL] [Abstract][Full Text] [Related]
39. Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease.
Gispert JD; Suárez-Calvet M; Monté GC; Tucholka A; Falcon C; Rojas S; Rami L; Sánchez-Valle R; Lladó A; Kleinberger G; Haass C; Molinuevo JL
Alzheimers Dement; 2016 Dec; 12(12):1259-1272. PubMed ID: 27423963
[TBL] [Abstract][Full Text] [Related]
40. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
